Basecamp Research Raises $140M to Advance AI-Designed Medicines

Basecamp Research’s new financing is a bet that genetic diversity found in nature can help design medicines. The London-based company plans to train a new generation of its EDEN biological AI models and move AI-designed therapies toward clinical development. Those plans are ambitious, but the funding announcement is not evidence that the treatments work in patients. 1528

What the $140 million round funds

Basecamp announced its oversubscribed Series C on 23 September 2026. S32 led the $140 million round, which valued the company at $800 million, according to Reuters. Reported total funding now stands at $225 million. 118

The proceeds are intended to expand EDEN and advance a preclinical pipeline, initially focused on in vivo cell therapy. That approach aims to reprogram cells inside a patient’s body rather than establish that any such treatment is ready for clinical use. Reporting identifies cancer and autoimmune diseases among the areas Basecamp hopes to address. 35830

Who invested?

S32, the round’s lead investor, was founded by Bill Maris, who also founded GV, Alphabet’s venture-capital arm. Nvidia participated through its venture arm NVentures, described as a returning investor. Menlo Ventures’ Anthology Fund, a partnership with Anthropic, was described as a new investor. 14

Other named participants include Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. The available investor lists name participants but do not establish which of each of these firms were new or returning backers. 59

Why biodiversity matters to Basecamp’s AI

Basecamp’s strategy is to use genomic data drawn from many species to train EDEN for biological design, then apply those models to therapeutic development. A description of its BaseData platform says it spans billions of genes from more than a million species; reporting describes a biodiversity-data network extending across roughly 30 countries. Those figures describe the scale of the reported data effort, not demonstrated medical effectiveness. 182628

One reported line of work involves AI-designed recombinases—enzymes investigated for inserting large DNA payloads at specified genomic sites. It helps explain Basecamp’s interest in more complex cell therapies, but the available evidence does not establish that its approach has overcome delivery challenges, reduced manufacturing costs or improved outcomes for patients. 27

The milestone that still matters

Basecamp, reported to have been founded in 2019, has disclosed a six-program pipeline and plans to move its therapeutics toward clinical development. The cited reporting describes results to date as preclinical and does not provide published, program-by-program clinical outcomes. The Series C gives the company resources to test its premise; whether biodiversity-trained AI can produce safe, effective treatments remains to be shown. 182330